Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $193.7 million.

  • Ani Pharmaceuticals' Total Current Liabilities rose 42.45% to $270.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.6 million, marking a year-over-year increase of 42.45%. This contributed to the annual value of $193.7 million for FY2024, which is 33.13% up from last year.
  • Ani Pharmaceuticals' Total Current Liabilities amounted to $193.7 million in FY2024, which was up 33.13% from $145.5 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Total Current Liabilities ranged from a high of $193.7 million in FY2024 and a low of $78.6 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $145.5 million (2023), whereas its average is $146.2 million.
  • Data for Ani Pharmaceuticals' Total Current Liabilities shows a peak YoY spiked of 46.30% (in 2023) over the last 5 years.
  • Ani Pharmaceuticals' Total Current Liabilities (Yearly) stood at $78.6 million in 2020, then climbed by 11.42% to $87.5 million in 2021, then rose by 13.60% to $99.4 million in 2022, then skyrocketed by 46.30% to $145.5 million in 2023, then skyrocketed by 33.13% to $193.7 million in 2024.